Damodaran's identity — Expected Operating-Income Growth = Reinvestment Rate × RoIC — is the single most powerful arithmetic discipline a long-term Indian investor can carry. This educational lesson decodes the formula and applies it to Titan Biotech FY25 audited markers as a positive illustration of disciplined capital allocation.

Slovic, Finucane, Peters and MacGregor's 2002 Affect Heuristic — feel first, justify second — explains the silent operating system behind Indian retail flows, F&O losses and festival SIP spikes. A counter-measure checklist, a Graham/Buffett/Munger/Klarman lineage, and a positive corporate case-study using Titan Biotech FY25 audited numbers.

Learn how to read a company's Sales-to-Gross-Block ratio in 60 seconds — the asset-productivity test that separates capital-light compounders from capital-heavy laggards. Titan Biotech FY25's ~3.76x reading is the positive illustration.

Tversky & Kahneman's 1981 Asian Disease Problem proved that human preferences reverse under arithmetically identical framings. Indian retail data confirms the effect at industrial scale. Titan Biotech (BSE: 524717) FY25 disclosures publish nearly every material fact in two frames simultaneously — a corporate analogue of the dual-frame discipline the great investors have used for ninety years.